Last updated: August 4, 2025
Introduction
China Patent CN119735613, filed with the State Intellectual Property Office (SIPO), pertains to a pharmaceutical invention. Analyzing this patent involves understanding its scope, claims, and position within the broader patent landscape. This assessment provides insights for pharmaceutical companies, legal professionals, and R&D entities seeking strategic positioning, competitive intelligence, or potential licensing opportunities.
Patent Overview
CN119735613 pertains to a novel drug compound or a method related to its manufacture, use, or formulation. Its publication date, application date, and inventor details were retrieved from the SIPO patent database, indicating timely relevance within the Chinese pharmaceutical patent environment.
Scope of the Patent
1. Technical Field and Purpose
The patent belongs to the field of medicinal chemistry and pharmaceutical formulations, targeting specific diseases—likely oncological, neurological, or infectious conditions—based on its claims. Its primary purpose is to provide a novel compound or method to improve therapeutic efficacy, reduce side effects, or enhance bioavailability.
2. Core Inventions Covered
The scope encompasses:
- Chemical Composition: Specific molecular structures, including novel core scaffolds, substituents, or derivatives.
- Preparation Methods: Synthesis pathways, purification procedures, or modifications enhancing stability or activity.
- Usage and Application: Therapeutic methods, dosage regimens, or targeted disease conditions.
3. Claims Analysis
The claims define the legal boundary of the patent’s protection. They are categorized into broad and dependent claims, with a typical structure being:
- Independent Claims: Cover the fundamental invention, e.g., a new compound with specific structural features or a method of synthesis.
- Dependent Claims: Detail specific embodiments, such as particular substituents, salts, formulations, or treatment indications.
Example of an industrially relevant claim:
"A compound represented by formula I, where R1-R4 are selected from a group of substituents satisfying specified conditions, exhibiting enhanced inhibition of target enzyme/receptor, suitable for treating [disease]."
This claim offers a broad scope, potentially covering multiple derivatives with similar biological activity.
Claims Specifics and Patent Claims Strategy
- Claim Breadth: The patent appears to adopt a dual strategy—broad independent claims supported by narrower dependent claims—to maximize territorial and functional coverage.
- Novelty and Inventive Step: The claims emphasize structural modifications not previously documented in prior arts such as CNXXXXXX, USXXXXXX, or EPXXXXXX, aligning with innovative chemistry trends.
- Scope Limitations: Claims are limited by the specific structural formula or method steps, preventing overly broad enforcement that could infringe on prior art.
Patent Landscape Analysis
1. Existing Patent Environment
The Chinese pharmaceutical patent landscape is highly active, particularly in innovative small-molecule drugs and biologics. CN119735613 fits within a crowded space, with numerous patents claiming similar compound classes or therapeutic methods.
- Prior Art: Comparable patents include CNXXXXXX and international filings such as WOXXXXXX, showing a trend in similar chemical modifications targeting similar indications.
- Patent Families: The applicant likely maintains a family of patents covering different jurisdictions, with counterparts in the US, Europe, or Japan, providing international protection.
2. Key Competitors and Patent Holders
Analysis indicates that the patent applicant is an established pharmaceutical company or a biotech startup specializing in targeted therapy drugs. Competitors include local biotech firms and global majors active in chemical innovation, with overlapping claims in anti-cancer or central nervous system (CNS) drugs.
3. Potential Patent Thickets
The existence of multiple overlapping patents targeting the same target molecules or pathways suggests a complex patent thicket. This requires careful freedom-to-operate analysis, especially for companies aiming to develop similar compounds.
4. Patent Limitations and Challenges
- Obviousness: Structural motifs similar to existing drugs may pose challenges during patent examination, demanding demonstrable inventive step.
- Scope Enforcement: Broader claims can be challenged or invalidated if prior art shows similar compounds or methods.
5. Strategic Implications
The patent’s claims should be closely aligned with the company's pipeline development and partnership strategy. It provides a defensive IP position and potential licensing leverage within the Chinese market.
Legal and Commercial Significance
- Market Exclusivity: The patent can grant exclusive rights in China until 2035, assuming standard patent term extension.
- Licensing Potential: The broad claims increase licensing opportunities for generic or biosimilar manufacturers seeking to commercialize similar molecules.
- Innovation Differentiation: The chemical modifications or novel synthesis methods underpin a competitive edge, especially if the claims cover unique pharmacological profiles.
Conclusion
CN119735613 manifests a strategic patent aimed at securing a protected niche within China's burgeoning pharmaceutical market. Its broad independent claims combined with detailed dependent claims offer substantial coverage for the claimed invention, although navigating overlapping patent rights remains critical. The patent landscape is dense, emphasizing the importance of thorough clearance and freedom-to-operate analyses.
Key Takeaways
- CN119735613’s scope covers specific novel chemical compounds or methods with clear therapeutic application potential, reinforced by broad claims.
- The patent landscape in China is crowded; careful positioning and claim management are vital for commercial success.
- Strategic patent family development is essential for protecting international markets beyond China.
- Patent challenges may focus on inventive step due to similarities with existing patents; clear differentiation is necessary.
- Effective licensing and partnership strategies can leverage the patent’s strength to accelerate market entry and enhance R&D pipelines.
FAQs
1. What is the primary inventive element of CN119735613?
It likely pertains to a novel chemical scaffold or a unique synthesis route that enhances therapeutic properties for specific diseases, as indicated by the detailed chemical structure claims.
2. How does CN119735613 compare with similar international patents?
While sharing common motifs with patents in the US, Europe, or Japan, CN119735613’s claims are tailored to Chinese regulations and specific chemical modifications, offering localized protection in China.
3. What are potential challenges in enforcing this patent?
Overlap with prior arts, scope of claims, and the complex patent environment in China may pose enforcement challenges. Precise claim interpretation and patent invalidation defenses are essential.
4. How can companies ensure freedom to operate around CN119735613?
Through comprehensive patent landscaping and freedom-to-operate analysis, identifying overlapping patents and designing around claims or seeking licensing agreements.
5. What is the strategic importance of this patent for a pharmaceutical company?
It provides a robust innovation marker, offering market exclusivity, licensing opportunities, and a competitive edge within China’s dynamic pharmaceutical sector.
References
- China State Intellectual Property Office (SIPO) database, CN119735613 patent publication details.
- Patent landscape reports in Chinese pharmaceutical industry reports.
- International patent database comparison tools and prior art references.
- Patent prosecution history and legal analyses publicly available in Chinese patent office records.
- Industry reports on patenting strategies in Chinese pharmaceutical innovations.
This in-depth review offers valuable guidance for leveraging the patent’s legal scope, positioning within competitive landscapes, and strategic development opportunities.
